Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 13;85(15):1325-31.
doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

Agustí Alentorn  1 , Caroline Dehais  1 , François Ducray  1 , Catherine Carpentier  1 , Karima Mokhtari  1 , Dominique Figarella-Branger  1 , Olivier Chinot  1 , Elisabeth Cohen-Moyal  1 , Carole Ramirez  1 , Hugues Loiseau  1 , Selma Elouahdani-Hamdi  1 , Patrick Beauchesne  1 , Olivier Langlois  1 , Christine Desenclos  1 , Jean-Sébastien Guillamo  1 , Phong Dam-Hieu  1 , François Ghiringhelli  1 , Philippe Colin  1 , Joel Godard  1 , Fabrice Parker  1 , Frédéric Dhermain  1 , Antoine F Carpentier  1 , Jean-Sebastien Frenel  1 , Philippe Menei  1 , Luc Bauchet  1 , Thierry Faillot  1 , Mélanie Fesneau  1 , Denys Fontaine  1 , Marie-Jeannette Motuo-Fotso  1 , Elodie Vauleon  1 , Claude Gaultier  1 , Caroline Le Guerinel  1 , Edouard-Marcel Gueye  1 , Georges Noel  1 , Nicolas Desse  1 , Xavier Durando  1 , Eduardo Barrascout  1 , Michel Wager  1 , Damien Ricard  1 , Ioana Carpiuc  1 , Jean-Yves Delattre  1 , Ahmed Idbaih  2 ; POLA Network
Collaborators, Affiliations

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

Agustí Alentorn et al. Neurology. .

Abstract

Objectives: We aimed to study the potential clinical relevance of 9p allelic loss, with or without copy number variation, in 1p/19q codeleted anaplastic oligodendroglial tumors (AOTs).

Methods: This study enrolled 216 patients with 1p/19q codeleted AOT. The prognostic value of 9p allelic loss was investigated using a French nation-wide prospective registry, POLA (prise en charge des tumeurs oligodendrogliales anaplasiques) and high-density single nucleotide polymorphism arrays. We validated our results using the Repository of Molecular Brain Neoplasia Data (REMBRANDT) dataset.

Results: The minimal common region of allelic loss in chromosome arm 9p was 9p21.3. Allelic loss of 9p21.3, detected in 41.7% of tumors, was associated with shorter progression-free and overall survival rates in univariate (p = 0.008 and p < 0.001, respectively) and multivariate analyses (p = 0.009 and p = 0.009, respectively). This finding was validated in the REMBRANDT dataset in univariate and multivariate analysis (p = 0.01 and p = 0.01, respectively).

Conclusion: Our study highlights a novel potential prognostic biomarker in 1p/19q codeleted AOT. Further prospective studies are warranted to investigate our finding.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Minimal common region of allelic loss in a 1p/19q codeleted anaplastic oligodendroglial tumor harboring 9p21.3 allelic loss
The different panels show the frequencies of the different mechanisms of loss of heterozygosity (LOH). MCR = minimal common region.
Figure 2
Figure 2. Kaplan-Meier curves in 1p/19q codeleted anaplastic oligodendroglial tumor according to 9p21.3 loss
Progression-free survival (PFS) (A) and overall survival (OS) (B) according to 9p23.1 allelic status. C = 1p/19q codeletion without 9p21.3 allelic loss; C+9p = 1p/19q codeletion with 9p21.3 allelic loss; HR = hazard ratio.
See this image and copyright information in PMC

References

    1. Van den Bent MJ, Bromberg JEC. Anaplastic oligodendroglial tumors. Handb Clin Neurol 2012;105:467–484. - PubMed
    1. Louis DN, Perry A, Burger P, et al. International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429–435. - PMC - PubMed
    1. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021–6026. - PMC - PubMed
    1. Van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–350. - PubMed
    1. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–343. - PMC - PubMed

Publication types